Get the Stockscreener App
3.84
0.92%
0.02
After Hours:
3.85
0.01
+0.26%
Myriad Genetics Inc stock is traded at $3.84, with a volume of 832.77K.
It is up +0.92% in the last 24 hours and down -19.35% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$3.82
Open:
$3.83
24h Volume:
832.77K
Relative Volume:
0.44
Market Cap:
$362.68M
Revenue:
$829.00M
Net Income/Loss:
$-399.90M
P/E Ratio:
-0.8897
EPS:
-4.3159
Net Cash Flow:
$-23.20M
1W Performance:
+8.59%
1M Performance:
-19.35%
6M Performance:
-49.28%
1Y Performance:
-1.41%
1-Day Range:
$3.72
$3.88
1-Week Range:
$3.535
$3.95
52-Week Range:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.84 | 360.79M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
448.84 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.86 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
558.02 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
339.50 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.14 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
MYGN Technical Analysis & Stock Price Forecast - Intellectia AI
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35 - MSN
Myriad Genetics | 5/22/26 - ktnv.com
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships - Traders Union
‘American Idol’ Star Speaks Out on Health Issues 17 Years After Show Appearance - Parade
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN) - Yahoo Finance
Myriad Genetics in record sell-off after Q1 miss - MSN
Stocks With 20% Upside: Dollar Tree, Myriad Genetics, Antero Resources AnalysisNews and Statistics - IndexBox
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics, Inc. $MYGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Jackie Tohn joins Myriad Genetics in campaign to expand hereditary cancer test awareness - Traders Union
Myriad Genetics, Inc.Common Stock (NQ: MYGN - FinancialContent
Myriad Genetics and actress Jackie Tohn promote hereditary cancer testing after her BRCA1 gene discovery. - Pluang
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life - markets.businessinsider.com
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing Awareness - Quiver Quantitative
Insider Buying: Paul Bisaro Acquires Shares of Myriad Genetics I - GuruFocus
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Myriad Genetics director Paul Bisaro buys $27,637 in stock By Investing.com - Investing.com Australia
Myriad Genetics director Paul Bisaro buys $27,637 in stock - Investing.com UK
Paul Bisaro (NASDAQ: MYGN) adds 7,500 Myriad Genetics shares - Stock Titan
Myriad Genetics Inc stock (US62855J1043): shares react to Q1 2025 results and updated 2025 guidance - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan - SelectScience
Myriad Genetics unveils ultra-sensitive MRD testing focus at Tokyo oncology summit - Traders Union
Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop - AD HOC NEWS
State Street (MYGN) reports 4.42M Myriad shares, 4.7% stake - Stock Titan
FirstGene Multiple Prenatal Screen launch drives engagement at ACOG2026, Myriad Genetics advances genetic care - Traders Union
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock - Insider Monkey
Myriad Genetics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MYGN) 2026-05-08 - Seeking Alpha
Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a Promising 77.94% Upside Potential - DirectorsTalk Interviews
Hereditary Cancer Testing Market Will Generate Booming Growth - openPR.com
Myriad Genetics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Myriad Genetics Is Maintained at Hold by TD Cowen - Moomoo
Myriad Genetics to join two healthcare conferences in upcoming weeks - Traders Union
Myriad Genetics to join BofA meetings, Goldman webcast in June - Stock Titan
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - GlobeNewswire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Myriad Genetics Bets on Growth Amid Profit Squeeze - TipRanks
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns - Sahm
Myriad Genetics (MYGN) reports Q1 loss, misses revenue estimates - MSN
Myriad Genetics Q1 2026 earnings preview - MSN
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Myriad Genetics Inc Stock (MYGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raha Samraat S. | President and CEO |
Mar 09 '26 |
Buy |
5.00 |
40,000 |
199,844 |
493,104 |
| Phanstiel S. Louise | Director |
Feb 26 '26 |
Buy |
4.80 |
50,407 |
242,105 |
233,951 |
| Phanstiel S. Louise | Director |
Feb 27 '26 |
Buy |
4.66 |
48,000 |
223,728 |
281,951 |
| Phanstiel S. Louise | Director |
Feb 25 '26 |
Buy |
4.74 |
6,100 |
28,890 |
183,544 |
0.23%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):